Why the study?
What is the current therapeutic management of acute pulmonary embolism based on risk stratification?
What is the current therapeutic management of acute pulmonary embolism based on risk stratification?
This review highlights that DOACs are the preferred first-line therapy for non-high risk acute pulmonary embolism, whereas systemic thrombolysis or thrombectomy should be reserved for high-risk patients in shock.
Answers are grounded in this paper and cite their sources.
Reinforces guideline-aligned DOAC use in non-high-risk PE; leaves open prospective trials on thrombectomy thresholds.
INTRODUCTION: Acute pulmonary embolism (PE) is a potentially fatal manifestation of venous thromboembolism. Prompt anticoagulant treatment is crucial for PE patients, which can decrease morbidity and mortality. Risk assessment is the cornerstone of the therapeutic management of PE. It guides physicians to the most appropriate treatment and selects patients for early discharge or home treatment. Areas covered: Here, we review the current treatments of acute PE according to contemporary risk stratification strategies, highlighting each step of PE therapeutic management. Expert commentary: Currently, direct oral anticoagulants (DOACs) represent the first-line therapy of patients presenting with non-high risk PE with a better risk-benefit ratios than vitamin K antagonists (VKAs) due to lower risk of major bleeding. Only high-risk patients with PE who present in shock should be treated with systematic thrombolysis, while surgical thrombectomy or catheter direct thrombolysis (CDT) should only be considered when thrombolysis is contraindicated because of too high bleeding risk.
No takes yet. Share an insight, caveat, or question.
Tromeur et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: